Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Direxion Daily MSFT Bull 2X ETF (NQ:MSFU)

23.50 -1.40 (-5.62%)
Streaming Delayed Price Updated: 10:39 AM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Direxion Daily MSFT Bull 2X ETF

News headline image
Tesla, Nvidia, Palantir ETFs Dominate As Traders Pile Into High-Risk Bets In June ↗
Traders rushed into leveraged ETFs tied to Tesla, Nvidia, and Palantir in June, signaling renewed risk appetite in tech. 
Via Benzinga
Topics ETFs
News headline image
EXCLUSIVE: Tech Valuations 'Pricey', Cybersecurity 'Top Of Mind' Ahead Of US Elections ↗
The tech sector has been the engine driving stock market gains this year, with giants like Apple Inc (NASDAQ:AAPL), Microsoft Corp (NASDAQ:MSFT) and Nvidia Corp (NASDAQ: 
Via Benzinga
News headline image
Tesla Bear? Nvidia Bull? Leveraged And Inverse Single Stock ETFs Can Help You Maximize Your View ↗
 
Via Benzinga
Topics ETFs
News headline image
Microsoft Moves Toward All-Time Highs Ahead Of Federal Reserve Meeting Minutes: A Technical Analysis ↗
Microsoft Corporation (NASDAQ: MSFT) was trading slightly higher Wednesday, appearing to work its way back toward the March 14 all-time high of $427.82. 
Via Benzinga
Topics Economy
News headline image
Could This Be Another Big Year for the Biggest Company in the World? 2 Key Factors Propelling Microsoft in 2024 ↗
AI 
Via Benzinga
Topics Artificial Intelligence
News headline image
Leveraged Tech ETFs Enjoying Huge Rally ↗
The technology sector has staged a strong comeback this year and is once again dominating the stock market rally. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.